or Try an Advanced Search...

    Technical Analysis for ALGS - Aligos Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.37 5.43% 0.02
    ALGS closed up 5.43 percent on Monday, July 1, 2024, on 5.02 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ALGS trend table...
    Date Alert Name Type % Chg
    Volume Surge Other 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 5.43%
    Volume Surge Other 5.43%
    New 52 Week Low Weakness 5.43%
    Earnings Movers Other 5.43%
    Wide Bands Range Expansion 5.43%
    Down 3 Days in a Row Weakness 5.43%
    Down 4 Days in a Row Weakness 5.43%
    Older End-of-Day Signals for ALGS ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 11 hours ago
    Up 1% about 11 hours ago
    Up 1% 3 days ago
    5x Volume Pace 3 days ago
    Lower Bollinger Band Support 3 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ALGS Chart by TradingView
    Basic chart:

    Profile

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Clinical Medicine Alcohol Drug Development Coronavirus Hepatitis B Hepatitis Steatohepatitis Viruses Non Alcoholic Fatty Liver Disease Liver Disease Viral Disease Viral Infections Antiviral Therapies Chronic Hepatitis Viral Infection

    Is ALGS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 26 AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection
    Jun 24 GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance
    Jun 19 Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
    Jun 18 AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
    Jun 5 Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
    Jun 4 Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now
    May 22 Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
    May 16 After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)
    May 9 Aligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)
    May 8 Aligos Therapeutics reports Q1 results
    See more ALGS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.2
    52 Week Low 0.3482
    Average Volume 357,100
    200-Day Moving Average 0.73
    50-Day Moving Average 0.62
    20-Day Moving Average 0.48
    10-Day Moving Average 0.41
    Average True Range 0.05
    RSI (14) 25.37
    ADX 34.81
    +DI 13.63
    -DI 22.89
    Chandelier Exit (Long, 3 ATRs) 0.49
    Chandelier Exit (Short, 3 ATRs) 0.51
    Upper Bollinger Bands 0.64
    Lower Bollinger Band 0.32
    Percent B (%b) 0.16
    BandWidth 67.50
    MACD Line -0.08
    MACD Signal Line -0.07
    MACD Histogram -0.0042
    Fundamentals Value
    Market Cap 26.57 Million
    Num Shares 72 Million
    EPS -1.89
    Price-to-Earnings (P/E) Ratio -0.20
    Price-to-Sales 3.14
    Price-to-Book 0.93
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.44
    Resistance 3 (R3) 0.45 0.42 0.43
    Resistance 2 (R2) 0.42 0.40 0.42 0.43
    Resistance 1 (R1) 0.40 0.39 0.41 0.39 0.42
    Pivot Point 0.37 0.37 0.38 0.37 0.37
    Support 1 (S1) 0.35 0.35 0.36 0.34 0.32
    Support 2 (S2) 0.32 0.34 0.32 0.31
    Support 3 (S3) 0.30 0.32 0.31
    Support 4 (S4) 0.29